Business Description
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
Business History
Price Overview
Last updated: Jun 27, 2026 9:04am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -1.65
Total Equity: -$31.46M
Shares: 30,476,000
Total Debt: $0.00
Cash: $11.58M
EBITDA: -$47.92M
Total Debt: $0.00
Cash: $11.58M
Revenue: $4.06M
Shares: 30,476,000
Revenue: $4.06M
Revenue: $4.06M
Revenue: $4.06M
Total Equity: -$31.46M
Tax Rate: 0.0%
Equity: -$31.46M
Total Debt: $0.00
Cash: $11.58M
Current Liabilities: $12.08M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: -$31.46M
Shares: 30,476,000
Shares: 30,476,000
CapEx: -$3.19M
Shares: 30,476,000
Stock Price: $5.40
Net Income: -$50.22M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 26, 2026 11:06pm (9h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.2M | $958,000 | $1.5M | $1.9M | $4.1M |
| Cost of Revenue | $778,000 | $976,000 | $1.1M | $1.1M | $3.9M |
| Gross Profit | $1.4M | $-18,000 | $413,000 | $740,000 | $190,000 |
| Operating Expenses | $55.1M | $18.0M | $25.5M | $61.8M | $30.8M |
| Operating Income | -$53.7M | -$18.0M | -$25.1M | -$61.0M | -$30.6M |
| Net Income | -$64.1M | -$72.9M | -$27.8M | -$60.7M | -$50.2M |
| EBITDA | -$48.5M | -$13.3M | -$23.1M | -$59.0M | -$47.9M |
| EPS | $-14.40 | $-20.00 | $-3.75 | $-4.66 | $-1.65 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 26, 2026 11:06pm (9h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $32.9M | $20.0M | $9.4M | $8.6M | $11.6M |
| Total Current Assets | $39.1M | $25.5M | $10.7M | $11.8M | $15.3M |
| Total Assets | $159.6M | $100.1M | $74.9M | $35.1M | $25.8M |
| Current Liabilities | $14.1M | $12.1M | $7.2M | $7.3M | $12.1M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $94.3M | $60.5M | $54.4M | $47.4M | $57.2M |
| Total Equity | $65.2M | $39.6M | $20.5M | -$12.3M | -$31.5M |
| Retained Earnings | -$187.8M | -$260.7M | -$289.9M | -$350.5M | -$400.8M |
Cash Flow (Annual)
Last updated: Jun 26, 2026 11:06pm (9h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$35.9M | -$45.6M | -$23.3M | -$20.7M | -$22.2M |
| Capital Expenditure | -$2.2M | -$4.3M | $-281,000 | $-516,000 | -$3.2M |
| Free Cash Flow | -$38.2M | -$49.9M | -$23.6M | -$21.2M | -$25.4M |
| Acquisitions (net) | -$11.7M | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $-239,000 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $28.5M | -$14.1M | -$12.1M | $-796,000 | $3.7M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 11:06pm (9h ago)| Metric | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Revenue |
$3.2M $3.2M – $3.3M
|
$2.1M $988,902 – $3.0M
|
$7.7M $1.3M – $11.9M
|
$29.3M $6.8M – $44.2M
|
| EBITDA |
-$3.2M -$3.3M – -$3.2M
|
-$2.1M -$3.0M – $-988,902
|
-$7.7M -$11.9M – -$1.3M
|
-$29.3M -$44.2M – -$6.8M
|
| Net Income |
-$47.8M -$58.0M – $-43,951
|
-$28.9M -$42.3M – $-32,051
|
-$31.5M -$43.1M – $-32,627
|
-$27.5M -$40.0M – $-30,324
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 26, 2026 11:06pm (9h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -56.4% | +56.9% | +25.1% | +115.6% |
| Gross Profit Growth | -101.3% | +2,394.4% | +79.2% | -74.3% |
| Operating Income Growth | +66.5% | -39.7% | -142.8% | +49.9% |
| Net Income Growth | -13.7% | +61.9% | -118.4% | +17.2% |
| EBITDA Growth | +72.5% | -73.7% | -155.2% | +18.8% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-11 | SILVERMAN LOU | A-Award | 26,943.00 | $0.00 | $0 |
| 2026-06-11 | Last Andrew J. | A-Award | 26,943.00 | $0.00 | $0 |
| 2026-06-11 | Arno Andrew | A-Award | 32,331.00 | $0.00 | $0 |
| 2026-04-27 | BROADWOOD PARTNERS, L.P. | P-Purchase | 0.00 | $0.00 | $0 |
| 2026-04-27 | BROADWOOD PARTNERS, L.P. | P-Purchase | 250,923.00 | $3.64 | $913,134 |
| 2026-04-24 | BROADWOOD PARTNERS, L.P. | P-Purchase | 38,880.00 | $3.53 | $137,083 |
| 2026-04-24 | BROADWOOD PARTNERS, L.P. | P-Purchase | 0.00 | $0.00 | $0 |
| 2026-04-23 | BROADWOOD PARTNERS, L.P. | P-Purchase | 0.00 | $0.00 | $0 |
| 2026-04-23 | BROADWOOD PARTNERS, L.P. | P-Purchase | 280,381.00 | $3.50 | $982,034 |
| 2026-04-20 | BROADWOOD PARTNERS, L.P. | P-Purchase | 0.00 | $0.00 | $0 |
| 2026-04-20 | BROADWOOD PARTNERS, L.P. | P-Purchase | 40,690.00 | $3.88 | $157,967 |
| 2026-04-17 | BROADWOOD PARTNERS, L.P. | P-Purchase | 0.00 | $0.00 | $0 |
| 2026-04-17 | BROADWOOD PARTNERS, L.P. | P-Purchase | 40,114.00 | $3.57 | $143,251 |
| 2026-04-16 | BROADWOOD PARTNERS, L.P. | P-Purchase | 102,057.00 | $3.45 | $351,658 |
| 2026-04-16 | BROADWOOD PARTNERS, L.P. | P-Purchase | 0.00 | $0.00 | $0 |
| 2026-03-26 | James Andrea S. | M-Exempt | 28,302.00 | $0.00 | $0 |
| 2026-03-26 | James Andrea S. | F-InKind | 11,298.00 | $4.11 | $46,435 |
| 2026-03-26 | James Andrea S. | M-Exempt | 28,302.00 | $0.00 | $0 |
| 2026-03-26 | Liu James Yang | M-Exempt | 6,289.00 | $0.00 | $0 |
| 2026-03-26 | Liu James Yang | M-Exempt | 6,289.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).